Exchange Traded Concepts LLC Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Exchange Traded Concepts LLC boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 6.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 319,682 shares of the company’s stock after buying an additional 20,031 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Omnicell were worth $14,232,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in Omnicell by 56.5% in the 4th quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock valued at $1,752,000 after purchasing an additional 14,202 shares in the last quarter. Arkadios Wealth Advisors boosted its position in Omnicell by 27.6% during the fourth quarter. Arkadios Wealth Advisors now owns 43,454 shares of the company’s stock worth $1,935,000 after acquiring an additional 9,404 shares during the last quarter. Accurate Wealth Management LLC raised its holdings in Omnicell by 33.4% in the 4th quarter. Accurate Wealth Management LLC now owns 28,369 shares of the company’s stock valued at $1,199,000 after acquiring an additional 7,109 shares during the last quarter. Nordea Investment Management AB lifted its stake in Omnicell by 4.3% in the 4th quarter. Nordea Investment Management AB now owns 121,722 shares of the company’s stock worth $5,372,000 after purchasing an additional 5,068 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of Omnicell by 49.9% during the 3rd quarter. Franklin Resources Inc. now owns 30,807 shares of the company’s stock worth $1,316,000 after purchasing an additional 10,260 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on OMCL shares. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Craig Hallum boosted their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.64% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL stock opened at $43.21 on Friday. The stock has a fifty day moving average price of $44.71 and a 200 day moving average price of $42.01. The stock has a market cap of $2.00 billion, a PE ratio of -110.36, a P/E/G ratio of 29.73 and a beta of 0.78. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.